Sanofi-Aventis Licenses CureDM's Early-Stage Diabetes Compound To Bolster Pipeline
Privately-held CureDM could receive up to $335 million in payments, plus sales royalties, from Sanofi-Aventis.
Privately-held CureDM could receive up to $335 million in payments, plus sales royalties, from Sanofi-Aventis.